Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1983 1
1985 1
1988 3
2003 4
2004 5
2007 10
2008 8
2009 3
2010 6
2011 8
2012 14
2013 4
2014 7
2015 4
2016 11
2017 12
2018 6
2019 10
2020 12
2021 16
2022 14
2023 17
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
In Reply.
Salani F, Ugolini C, Catanese S, Cacciato Insilla A, Fornaro L, Campani D, Vasile E, Fontanini G, Masi G, Vivaldi C. Salani F, et al. Among authors: ugolini c. Oncologist. 2021 Oct;26(10):e1895-e1896. doi: 10.1002/onco.13886. Epub 2021 Jul 17. Oncologist. 2021. PMID: 34176190 Free PMC article.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Antoniotti C, et al. Among authors: ugolini c. Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27. Lancet Oncol. 2022. PMID: 35636444 Clinical Trial.
In Reply.
Vivaldi C, Fornaro L, Ugolini C, Vasile E. Vivaldi C, et al. Among authors: ugolini c. Oncologist. 2020 Nov;25(11):e1819. doi: 10.1002/onco.13538. Epub 2020 Oct 3. Oncologist. 2020. PMID: 32969114 Free PMC article.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: ugolini c. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Predictive Biomarkers in Thyroid Cancer.
Macerola E, Poma AM, Vignali P, Proietti A, Ugolini C, Torregrossa L, Basolo A, Elisei R, Santini F, Basolo F. Macerola E, et al. Among authors: ugolini c. Front Oncol. 2022 May 6;12:901004. doi: 10.3389/fonc.2022.901004. eCollection 2022. Front Oncol. 2022. PMID: 35600349 Free PMC article. Review.
Molecular Genetics of Follicular-Derived Thyroid Cancer.
Macerola E, Poma AM, Vignali P, Basolo A, Ugolini C, Torregrossa L, Santini F, Basolo F. Macerola E, et al. Among authors: ugolini c. Cancers (Basel). 2021 Mar 7;13(5):1139. doi: 10.3390/cancers13051139. Cancers (Basel). 2021. PMID: 33799953 Free PMC article. Review.
Mediastinal dedifferentiated liposarcoma.
Sbrana F, Ugolini C, Taddei C, Alì G, Pasanisi EM. Sbrana F, et al. Among authors: ugolini c. Acta Cardiol. 2017 Aug;72(4):499-500. doi: 10.1080/00015385.2017.1335460. Epub 2017 Jul 14. Acta Cardiol. 2017. PMID: 28707566 No abstract available.
HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective.
Angerilli V, Parente P, Campora M, Ugolini C, Battista S, Cassoni P, Gambella A, Cavallin F, De Lisi G, Vanoli A, Grillo F, Mastracci L, Fassan M. Angerilli V, et al. Among authors: ugolini c. J Clin Pathol. 2023 Dec;76(12):815-821. doi: 10.1136/jcp-2023-208767. Epub 2023 Apr 13. J Clin Pathol. 2023. PMID: 37055161
Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis.
Viola N, Agate L, Caprio S, Lorusso L, Brancatella A, Ricci D, Sgrò D, Ugolini C, Piaggi P, Vitti P, Elisei R, Santini F, Latrofa F. Viola N, et al. Among authors: ugolini c. Endocr Relat Cancer. 2023 Jun 2;30(7):e230042. doi: 10.1530/ERC-23-0042. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37043372
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, Ugolini C, Proietti A, Conca V, Kassambara A, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, Tamburini E, Poma AM, Fieschi J, Fontanini G, Masi G, Galon J, Cremolini C. Moretto R, et al. Among authors: ugolini c. J Immunother Cancer. 2023 Apr;11(4):e006633. doi: 10.1136/jitc-2022-006633. J Immunother Cancer. 2023. PMID: 37085190 Free PMC article.
160 results